Home Tags Manufacturing

Tag: manufacturing

Emerging Trends in Single-Use Technology in the Manufacturing of Antibody-Drug...

Single-use technology, designed for the manufacturing of biopharmaceutical products, has made major inroads over the last 30 years. First introduced in the late 1970s...
Featured Image: Lonza, Visp, Switzerland. Courtesy: © 2010 - 2018 Lonza, Visp, Switzerland. Used with permission.

Lonza Expands Manufacturing Capacity for ADC Payloads

Lonza, a specialty contract development and manufacturing (CDMO) partner to the biopharma industry, will add new highly potent API (HPAPI) manufacturing suites at its...

Benefitting from the Worldwide Supply Chain in the development of Antibody-drug...

Timing is everything.Just over a decade ago, the pharmaceutical industry and R&D in China was dominated by generics and plagued with insufficient technical capacity...

Evolution of Antibody-Drug Manufacturing

Antibody-drug Conjugates (ADCs) have evolved since the initial approval of gemtuzumab ozogamicin (Mylotarg®) in 2000, with respect to conjugation, linker and toxin chemistries and...

ADC Biotechnology Invests in New Bioconjugation Facility in North Wales, United...

UK-based ADC Biotechnology has secured investment for the construction of an $11 million* bioconjugation facility at its new site in Deeside, North Wales, UK.The...

Evolving CMC Analytical Techniques for Biopharmaceuticals

1.0 Abstract During the (early) preclinical drug development process as well as manufacturing of biopharmaceutical (protein) products, analysis and characterization are crucial in gaining a...

Strategic Collaboration Between CMC Biologics and IDT Biologika to Manufacture Antibody...

Denmark-based CMC Biologics, a company involved in the clinical and commercial manufacturing of monoclonal antibodies and other therapeutic proteins, and IDT Biologika, a privately-held...
BT-062-Multiple-Myeloma-BIOTEST

Report Presents Latest Development in CMO Market for ADCs

While the basic concept of Antibody-drug Conjugates (ADCs), a new class of biopharmaceutical drugs designed as a targeted therapy, is quite simple - a biological active cytotoxic or chemotherapy drug, is delivered to the target tissue through linking it with a monoclonal antibody - the practical challenge of manufacturing such complex and highly toxic molecules is huge.